Q3 EPS Forecast for Cogent Biosciences Decreased by Analyst

Key Points

• Leerink Partners reduced their Q3 2025 earnings estimate for Cogent Biosciences from ($0.54) to ($0.55) per share, while also forecasting continued losses through FY2026 before projecting a profit in FY2027.
• Cogent Biosciences recently reported earnings of ($0.53) per share, slightly surpassing analysts' consensus estimate of ($0.55) by $0.02.
• Despite mixed ratings, the company has a current consensus rating of "Moderate Buy" with an average price target of $18.70, indicating a generally positive outlook from analysts.

Cogent Biosciences, Inc. (NASDAQ:COGT - Free Report) - Investment analysts at Leerink Partnrs cut their Q3 2025 earnings per share (EPS) estimates for shares of Cogent Biosciences in a research note issued on Tuesday, August 5th. Leerink Partnrs analyst A. Berens now anticipates that the technology company will post earnings of ($0.55) per share for the quarter, down from their previous estimate of ($0.54). The consensus estimate for Cogent Biosciences' current full-year earnings is ($2.42) per share. Leerink Partnrs also issued estimates for Cogent Biosciences' Q4 2025 earnings at ($0.57) EPS, FY2025 earnings at ($2.38) EPS, FY2026 earnings at ($1.49) EPS and FY2027 earnings at $0.97 EPS.

COGT has been the subject of several other reports. Leerink Partners boosted their target price on Cogent Biosciences from $16.00 to $18.00 and gave the stock an "outperform" rating in a research report on Monday, July 7th. JPMorgan Chase & Co. boosted their target price on Cogent Biosciences from $29.00 to $30.00 and gave the stock an "overweight" rating in a research report on Thursday. HC Wainwright decreased their price objective on Cogent Biosciences from $22.00 to $21.00 and set a "buy" rating for the company in a research report on Wednesday. Needham & Company LLC reiterated a "hold" rating on shares of Cogent Biosciences in a research report on Tuesday, June 17th. Finally, Citigroup boosted their price objective on Cogent Biosciences from $15.00 to $22.00 and gave the company a "buy" rating in a research report on Friday, July 18th. Three investment analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $18.70.

Cogent Biosciences Price Performance

Shares of Cogent Biosciences stock traded up $0.10 during trading on Friday, hitting $10.96. 1,331,775 shares of the company were exchanged, compared to its average volume of 2,409,835. The firm has a market capitalization of $1.25 billion, a P/E ratio of -6.16 and a beta of 0.36. Cogent Biosciences has a 1-year low of $3.72 and a 1-year high of $12.97. The firm's fifty day moving average price is $9.24 and its 200 day moving average price is $7.36.

Cogent Biosciences (NASDAQ:COGT - Get Free Report) last posted its earnings results on Tuesday, August 5th. The technology company reported ($0.53) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.55) by $0.02.

Insider Activity

In other Cogent Biosciences news, Director Fairmount Funds Management Llc acquired 2,777,777 shares of the business's stock in a transaction dated Thursday, July 10th. The shares were acquired at an average price of $9.00 per share, with a total value of $24,999,993.00. Following the completion of the transaction, the director directly owned 9,003,418 shares in the company, valued at $81,030,762. This trade represents a 44.62% increase in their position. The purchase was disclosed in a filing with the SEC, which can be accessed through the SEC website. 7.29% of the stock is owned by company insiders.

Institutional Investors Weigh In On Cogent Biosciences

Several hedge funds and other institutional investors have recently added to or reduced their stakes in COGT. Janus Henderson Group PLC lifted its position in Cogent Biosciences by 84.3% during the 4th quarter. Janus Henderson Group PLC now owns 29,073 shares of the technology company's stock worth $227,000 after buying an additional 13,300 shares in the last quarter. Ameriprise Financial Inc. lifted its position in Cogent Biosciences by 78.6% during the 4th quarter. Ameriprise Financial Inc. now owns 21,499 shares of the technology company's stock worth $168,000 after buying an additional 9,459 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its position in Cogent Biosciences by 15.1% during the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 135,604 shares of the technology company's stock worth $1,058,000 after buying an additional 17,741 shares in the last quarter. ProShare Advisors LLC lifted its position in Cogent Biosciences by 30.5% during the 4th quarter. ProShare Advisors LLC now owns 31,074 shares of the technology company's stock worth $242,000 after buying an additional 7,267 shares in the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in Cogent Biosciences by 7.0% during the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 58,582 shares of the technology company's stock worth $456,000 after buying an additional 3,831 shares in the last quarter.

Cogent Biosciences Company Profile

Cogent Biosciences, Inc, a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors.